Skip to main content
logo
Quince Therapeutics, Inc. (QNCX)
NASDAQ: QNCX · Real-Time Price · USD
32.15
+0.04 (0.12%)
Sep 2, 2026, 4:00 PM EDT - Market closed

Quince Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Selling, General & Admin
27.8115.0517.5815.424.9129.52
Research & Development
32.9935.3818.599.2525.1860.8
Operating Expenses
60.850.4336.1724.6450.0990.32
Operating Income
-60.8-50.43-36.17-24.64-50.09-90.32
Interest & Investment Income
1.271.242.933.481.070.62
Currency Exchange Gain (Loss)
0.490.49-0.680-0.77-0.25
Other Non Operating Income (Expenses)
19.69-22.38----
EBT Excluding Unusual Items
-39.35-71.08-33.92-21.16-49.79-89.95
Merger & Restructuring Charges
----2.5-1.1-
Impairment of Goodwill
---17.13--0.83-
Gain (Loss) on Sale of Assets
----0.04-0.09-
Asset Writedown
-67.81---5.97-0.14-
Other Unusual Items
71.52-9.68-5.69-1.92--
Pretax Income
-94.64-80.77-56.74-31.58-51.94-89.95
Income Tax Expense
-2.163.210.09-0.2-0.28-
Net Income
-92.48-83.98-56.83-31.39-51.66-89.95
Net Income to Common
-92.48-83.98-56.83-31.39-51.66-89.95
Net Income Growth
------
Shares Outstanding (Basic)
200000
Shares Outstanding (Diluted)
200000
Shares Change
704.22%15.80%16.18%11.17%12.71%1.86%
EPS (Basic)
-51.81-335.27-262.71-168.57-308.45-605.31
EPS (Diluted)
-51.81-335.27-262.71-168.57-308.45-605.31
EPS Growth
------

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
-47-41.78-32.16-18.45-44.17-63.11
Free Cash Flow Per Share
-26.33-166.78-148.68-99.11-263.73-424.73
EBITDA
-60.65-50.29-35.98-24.32-49.89-89.97
D&A For EBITDA
0.150.140.190.320.20.34
EBIT
-60.8-50.43-36.17-24.64-50.09-90.32
SEC Filings: 10-K · 10-Q